Navigation Links
Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
Date:1/6/2012

REDWOOD CITY, Calif., Jan. 6, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD. The first of these two trials (NCT01349803) was a 237-subject cardiovascular safety study designed to measure the change in mean heart rate following twice-daily (BID) chronic administration of the combination PT003, and its components PT001 and PT005. The second (NCT01349816) was a 185-patient, randomized, double-blind dose-confirmation study of different doses of PT003 compared with its components. PT003, PT001 and PT005 were shown to be safe, effective and well tolerated, with no meaningful changes in heart rate or other cardiovascular safety parameters relative to baseline as measured by Holter monitor over two weeks. Pearl plans to present results of these trials at appropriate medical meetings in 2012.

"We were able to conduct these two studies, as well as the previously announced Phase 2b dose-ranging studies of PT001 and PT005 in approximately six months, which is a testament to both the skill and commitment of our clinical team, and the efficacy and safety profiles of our combination bronchodilator observed to date," said Chuck Bramlage, chief executive officer for Pearl Therapeutics. "With this operational excellence, along with the continued safety and efficacy of our bronchodilator combination, we are confident in our plan to advance PT003, PT001 and PT005 into the rigor of late-stage clinical scrutiny."

These two clinical trials are part of the Company's five-study Phase 2b program that included three previously completed, randomized, double-blind trials: one dose-ranging trial each of PT005 and PT001, plus a placebo- and active-controlled
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
2. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
3. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
4. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
5. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
6. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
7. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
8. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
9. Anthera Announces Last Patient Enrolled in PEARL-SC Study
10. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
11. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- Market Research Report on Global and ... professional and in-depth market survey on Global ... report firstly reviews the basic information of X-Ray ... technology. The report then explores global and China,s ... product specification, capacity, Production value, and market share ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
Breaking Medicine Technology:Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3
... Open-label Extension of Phase II Study Demonstrates ... Mass., June 12, 2007 /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, ... Phase II EXPRESS trial for pagoclone in ... the 47th annual,meeting of the New Clinical ...
... activity reported against CTCL, PTCL and Ovarian ... -- CuraGen,Corporation , a clinical-stage biopharmaceutical company ... the clinical development,program for belinostat, a histone ... clinical activity of belinostat,against cutaneous T-cell lymphoma ...
Cached Medicine Technology:Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8
(Date:8/30/2014)... 2014 The establishment and creation ... been one of the main strategies of the ... positive impact around the world. , Architecturally stellar ... trained executives and trainers deliver L. Ron Hubbard's ... Vital statistics demonstrate that significant reduction in crime, ...
(Date:8/30/2014)... 30, 2014 After offering hyperbaric ... for the past several years, Dr. Roy Schmidt ... have announced a scholarship program for veterans who ... a meeting held this summer to discuss veterans’ ... reporters have shed light on the large number ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
(Date:8/30/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Cell Disruptor including ... then explores global and China’s top manufacturers of ... value, and market share etc. The report further ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... As the most trusted and,accessible health care ... health and make more than 80 million recommendations ... will follow these,recommendations. In fact, a recent survey, ... Patient Information and Education, found that,most Americans (80%) ...
... Commonly Prescribed Generic Drugs will be priced at $4 for a ... 30-day supply and $10 for a 90-day supply, ... its Stater Bros. Super Rx Pharmacy locations will begin,offering generic drugs ... the most commonly prescribed generic drugs will now be,available for the ...
... half had experienced it before or during college, survey ... between partners, friends and acquaintances is common before and ... 910 undergraduates aged 17 to 22 (57.1 percent female) ... , Among the findings: , , 407 (44.7 ...
... Inc.,(Nasdaq: THRM ), a leader in non-invasive ... it will present at the Collins Stewart LLC,Fourth ... in New York,City. Stephen J. Fanning, Chairman, President ... Officer, will review the Company,s,business strategy, historical financial ...
... In a New York City metro-area first, a 93-year-old ... at NewYork-Presbyterian Hospital, the only center on the Eastern ... new stent graft was implanted under an FDA-approved clinical ... a complex form of abdominal aortic aneurysms in which ...
... Seventh Annual Joint Conference With Centro Medical Paitilla to Focus on ... ... of physicians from Cleveland,Clinic will travel to Panama in mid July to ... Meeting. The,subject of this year,s conference is the Central Nervous System: Benign ...
Cached Medicine News:Health News:Stater Bros. Super Rx Pharmacy(SM) Now Offering $4 Generic Prescription Drugs 2Health News:Relationship Violence Common Among College Students 2Health News:NYC first: Complex aneurysm treated using new fenestrated endograft stent 2Health News:Cleveland Clinic Physicians to Present at Medical Conference in Panama, July 11-12 2Health News:Cleveland Clinic Physicians to Present at Medical Conference in Panama, July 11-12 3
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
DH Autoflow Single Chamber Stackable Air-Jacketed CO2 Incubator...
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
... from commonly used protein expression procedures using ... medium, contains two media, EXPANSION BROTH (EB) ... E. coli cells are grown in EB, ... is almost completely repressed. For high level ...
Medicine Products: